Reporting on market developments concerning 'Said the Dead' Review: The Patients Imprisoned Inside and Out. Industry analysts and investors are monitoring the operational, strategi...

Gilead Sciences raised its annual product sales guidance following robust performance in its core HIV business, driven by strong Biktarvy demand and solid operational execution.

Merck posted robust top-line gains driven by enduring demand for blockbuster oncology drug Keytruda and rapid market adoption of newly launched Winrevair.

Moderna Chief Executive Stéphane Bancel remains steadfast on the company's individualized cancer vaccine program despite recent equity selloffs and shifting market expectations.

HCA Healthcare shares came under heavy selling pressure as rising uninsured admissions and Medicaid redetermination fallout cloud profitability across the hospital sector.

Surgery Partners will be taken private in a landmark $5.7 billion acquisition by a Bon Secours affiliate, accelerating the consolidation wave across outpatient surgical care.

Shares of Genmab surged following encouraging clinical data from its oncology program, lifting sentiment across the European and U.S. biotechnology sectors.

U.S. Treasury plans to curb equity investments in Chinese biotech firms while keeping vital drug licensing channels open, balancing national security and drug development pipelines.